Dashboard

Financial News

Nano Labs Announces Second Half of 2025 Financial Results
benzinga83d ago

Nano Labs Announces Second Half of 2025 Financial Results

<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p>HANGZHOU, China, March 30, 2026 (GLOBE NEWSWIRE) -- Nano Labs Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/NA" rel="nofollow">NA</a>) ("we," the "Company" or "Nano Labs"), a leading Web 3.0 infrastructure and product solution provider and crypto treasury company today announced its unaudited financial results as of December 31, 2025 and for the six months ended December 31, 2025.</p> <p align="justify"><strong>Second Half of 2025 Financial Summary</strong></p> <ul> <li>Net revenue increased by 18.1% to RMB18.7 million (US$2.7 million) for the second half of 2025, from RMB15.9 million in the same period of 2024.</li> <li>Gross loss was RMB29.1 million (US$4.1 million) for the second half of 2025, compared to a gross profit of RMB11.6 million in the same period of 2024.</li> <li>Gain on change in fair value of cryptocurrencies was RMB130.0 million (US$18.5 million) for the second half of 2025, compared to a loss of RMB15.7 million in the same period of 2024.</li> <li>Profit from operations was RMB60.8 million (US$8.7 million) for the second half of 2025, compared to a loss of RMB55.6 million in the same period of 2024.</li> <li>Net income was RMB137.7 million (US$19.6 million) for the second half of 2025, compared to a net loss of RMB 60.4 million in the same period of 2024.</li> <li>Net income per share (both basic and diluted) was approximately RMB6.2 (US$0.9) for the second half of 2025, compared to a net loss per share (both basic and diluted) of approximately RMB6.0 in the same period of 2024.<br /><br /></li> </ul> <p align="justify">Mr. Jianping Kong, Chairman and Chief Executive Officer of the Company, commented: "2025 witnessed vigorous development in the Web 3.0 industry. With the continuous improvement of the global crypto market environment, including the enhancement of crypto asset infrastructure and rising market participation, the crypto market and Web 3.0-related sectors embraced a new phase of growth and opportunities.</p> <p align="justify">Following a comprehensive and meticulous internal assessment of BNB's strategic value and long-term prospects, we decided to take the lead in launching and continuously advancing the buildout of a BNB reserve. As of December 31, 2025, we held a total of 126,662 BNBs and a receivable for 3,338 BNBs collateral. By steadily increasing the BNB holdings, we have not only optimized our crypto asset allocation but also created favorable conditions for future business expansion and ecological collaboration.</p> <p align="justify">In terms of capital operations, we successfully completed two rounds of financing in 2025, which provided strong support for the Company's strategic transformation, the expansion of our crypto asset reserves, and the exploration of new business directions.</p> <p align="justify">In March 2026, we officially launched our new-generation product — iPollo ClawPC A1 Mini, designed to support the Open Claw AI Agent system. Subsequently, we plan to introduce the Claw OS system and more hardware products to further extend the full-chain ecological services for AI Agents.</p> <p align="justify">Meanwhile, to further enhance shareholder value and demonstrate the management's confidence in the Company's long-term development, we announced a share repurchase program of up to US$25.0 million in October 2025. This program has commenced and is expected to be implemented steadily over the long term.</p> <p align="justify">Looking ahead, we will continue to closely monitor emerging industry trends and market dynamics. While maintaining stable operations, we will further advance our crypto asset strategic reserve and pursue broader industrial opportunities in the AI Agent ecosystem."</p> <p align="justify">Mr. Bing Chen, Chief Financial Officer of the Company, added: "For the second half of 2025, our net revenue increased by 18.1% from RMB15.9 million to RMB18.7 million (US$2.7 million). In addition, we successfully turned to a net income of RMB137.7 million (US$19.6 million) for the six months ended December 31, 2025, compared to a net loss of RMB60.4 million in the same period of 2024. Adhering to the principles of long-termism and prudent decision-making, our management will continue to monitor and capture emerging opportunities arising in the transformation from Web 3.0 to Web 4.0, with the goal of creating sustainable long-term value for the Company and all shareholders."</p> <p align="justify"><strong>Second Half of 2025 Financial Results</strong></p> <p align="justify"><strong><em>Net Revenues</em></strong></p> <p align="justify">Net revenue was RMB18.7 million (US$2.7 million) for the second half of 2025, compared to RMB15.9 million for the same period of 2024. The increase was primarily due to the increase in sales volume of iPollo V Series.</p> <p align="justify"><strong><em>Cost of Revenues</em></strong></p> <p align="justify">Cost of revenues was RMB47.8 million (US$6.8 million) for the second half of 2025, compared to RMB4.3 million for the same period of 2024. The change was mainly due to the write-downs of inventories and value-added tax recoverable.</p> <p align="justify"><strong><em>Operating Income (Expenses)</em></strong></p> <p align="justify">Total operating income increased by 233.9% to RMB89.9 million (US$12.8 million) for the second half of 2025, compared to a total operating expenses of RMB67.1 million for the same period of 2024.</p> <ul> <li>Selling and marketing expenses decreased by 56.2% to RMB2.1 million (US$0.3 million) for the second half of 2025, from RMB4.8 million for the same period of 2024. The decrease in selling and marketing expenses was primarily due to the decrease in employee salary expenses.</li> <li>General and administrative expenses increased by 30.3% to RMB33.1 million (US$4.7 million) for the second half of 2025, from RMB25.4 million for the same period of 2024. The increase in general and administrative expenses was primarily due to the increase in professional services fees.</li> <li>Research and development expenses decreased by 76.9% to RMB4.9 million (US$0.7 million) for the second half of 2025, from RMB21.2 million for the same period of 2024. The decrease in research and development expenses was primarily due to the decrease in salary expenses, material fees, and equipment fees.</li> <li>Change in fair value of cryptocurrencies was a gain of RMB130.0 million (US$18.5 million) for the second half of 2025, compared to a loss of RMB15.7 million for the same period of 2024. The increase in gain from change in fair value of cryptocurrencies was primarily due to the increased BNB price during the second half of 2025.<br /><br /></li> </ul> <p align="justify"><strong><em>Profit (Loss) from Operations</em></strong></p> <p align="justify">Profit from operations was RMB60.8 million (US$8.7 million) for the second half of 2025, compared to loss from operations of RMB55.6 million for the same period of 2024.</p> <p align="justify"><strong><em>Finance Expenses</em></strong></p> <p align="justify">Finance expenses was RMB0.3 million (US$0.05 million) for the second half of 2025, compared to RMB2.0 million for the same period of 2024.</p> <p align="justify"><strong><em>Interest Expenses</em></strong></p> <p align="justify">Interest expenses was RMB11.7 million (US$1.7 million) for the second half of 2025, compared to RMB4.9 million for the same period of 2024. The change was due to the interest paid for the borrowings denominated in Bitcoin during the second half of 2025.</p> <p align="justify"><strong><em>Change in Fair Value of Borrowings Denominated in Cryptocurrencies</em></strong></p> <p align="justify">Change in fair value of borrowings denominated in cryptocurrencies was a gain of RMB60.5 million (US$8.6 million) for the second half of 2025, compared to nil for the same period of 2024. The change was due to the borrowings denominated in Bitcoin in 2025, which was measured at fair value and repaid before December 31, 2025.</p> <p align="justify"><strong><em>Other Income</em></strong></p> <p align="justify">Other income was RMB38.2 million (US$5.4 million) for the second half of 2025, compared to RMB1.7 million for the same period of 2024. The change was due to the Binance Launchpool and Airdrop income for BNB holders and income from crypto investment products.</p> <p align="justify"><strong><em>Other Expenses</em></strong></p> <p align="justify">Other expenses was RMB9.9 million (US$1.4 million) for the second half of 2025, compared to nil for the same period of 2024. The change was due to the loss from change in fair value of short-term investments during the second half of 2025.</p> <p align="justify"><strong><em>Net Income (Loss)</em></strong></p> <p align="justify">Net income was RMB137.7 million (US$19.6 million) for the second half of 2025, compared to a net loss of RMB60.4 million in the same period of 2024.</p> <p align="justify"><strong><em>Basic and Diluted Earnings or Loss Per Ordinary Share attributable to Nano Labs Ltd</em></strong></p> <p align="justify">Basic and diluted earnings per share was approximately RMB6.2 (US$0.9) for the second half of 2025, compared to basic and diluted loss per share of approximately RMB6.0 for the same period of 2024.</p> <p align="justify"><strong><em>Cash and Cash Equivalents</em></strong></p> <p align="justify">As of December 31, 2025, the Company had cash and cash equivalents of RMB8.5 million (US$1.2 million), compared to RMB32.4 million as of December 31, 2024.</p> <p align="justify"><strong>Exchange Rate</strong></p> <p align="justify">This press release contains translations of certain Renminbi (RMB) amounts into U.S. dollars (US$) solely for the convenience of the reader. Unless otherwise specified, all translations of Renminbi amounts into U.S. dollar amounts in this press release are made at RMB7.0288 to US$1.00, the central parity rate on December 31, 2025 published by the People's Bank of China.</p> <p align="justify"><strong>Non-GAAP Financial Measures</strong></p> <p align="justify">In evaluating our business, we consider and use adjusted net income/(loss) as an additional non-GAAP measure to review and assess our operating performance. The presentation of the non-GAAP financial measure is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP. We define adjusted net income/(loss) as net income/(loss) excluding share-based compensation expense.</p> <p align="justify">We present the non-GAAP financial measure because they are used by our management to evaluate our operating performance and formulate business plans. Non-GAAP financial measures enable our management to assess our operating results without considering the impact of non-cash charges and non-operating items. We also believe that the use of the non-GAAP measure facilitates investors' assessment of our operating performance.</p> <p align="justify">The non-GAAP financial measure is not defined under U.S. GAAP and is not presented in accordance with U.S. GAAP. The non-GAAP financial measure has limitations as analytical tools. One of the key limitations of using the non-GAAP financial measure is that they do not reflect all items of income and expense that affect our operations. Share-based compensation expenses have been and may continue to be incurred in our business and are not reflected in the presentation of adjusted net income/(loss). Further, the non-GAAP measure may differ from the non-GAAP information used by other companies, including peer companies, and therefore their comparability may be limited.</p> <p align="justify"><strong>Conference Call</strong></p> <p align="justify">The Company will host an earnings conference call to discuss its financial results at 8:30 am U.S. Eastern Time (8:30 pm Beijing Time) on March 30, 2026.</p> <p align="justify">For participants who wish to join the call, please access the link provided below to complete the online registration process.</p> <p align="justify">Registration Link: <a href="https://www.globenewswire.com/Tracker?data=EHNFtPyaorOHZ98_fDxCj2gLCtmjgMHpbWxTsK5QI0X9SPoBbjpq-Vz28iLlVtZr135pwcJxVzjod_C30pGpp0Cho8Cc8Idb_PM1-4tpkWJw_3YPz1K8uUdiocW-bkbBaYQBaQriTGTnOCmSfIX3ofIF7Tpkx8q4ptoJjKrYgi8nDzH3zVi98Kqf-A6ogwFd" rel="nofollow" target="_blank" rel="nofollow">https://s1.c-conf.com/diamondpass/10053968-bdhi7v.html</a></p> <p align="justify">Upon registration, participants will receive the dial-in number and unique PIN, which can be used to join the conference call. If participants register and forget their PIN or lose their registration confirmation email, they may simply re-register and receive a new PIN. All participants are encouraged to dial in 15 minutes prior to the start time.</p> <p align="justify">A live and archived webcast of the conference call will be accessible on the Company's investor relations website at: <a href="https://www.globenewswire.com/Tracker?data=EHNFtPyaorOHZ98_fDxCj7lXJE_K1fH7O1kW1y83mDmIwkBit1YBrwY2Kr1VUFu6s8rTj_mlzFlzqFvJ9dT6pVn-OoUgA6qqVT7LmSyyYuQ=" rel="nofollow" target="_blank" rel="nofollow">https://ir.nano.cn/</a>.</p> <p align="justify">A telephone replay of the call will be available until 6 April 2026 via the following dial-in details:</p> <p align="justify"><strong><u>Dial-in Numbers:</u></strong></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"> <tr> <td style="max-width:30%; width:30%; min-width:30%;;vertical-align: middle; text-align: left; padding-left: 25.0px; vertical-align: top ; ">US/Canada:</td> <td style="max-width:70%; width:70%; min-width:70%;;text-align: justify ; vertical-align: middle; vertical-align: top ; ">1855 883 1031</td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 25.0px; vertical-align: top ; "> </td> <td style="text-align: justify ; vertical-align: middle; vertical-align: top ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 25.0px; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Hong Kong:</td> <td style="text-align: justify ; vertical-align: middle; vertical-align: top ; ">800 930 639</td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 25.0px; text-align: justify ; vertical-align: middle; vertical-align: top ; "> </td> <td style="text-align: justify ; vertical-align: middle; vertical-align: top ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 25.0px; text-align: justify ; vertical-align: middle; vertical-align: top ; ">China:</td> <td style="text-align: justify ; vertical-align: middle; vertical-align: top ; ">400 1209 216</td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 25.0px; text-align: justify ; vertical-align: middle; vertical-align: top ; "> </td> <td style="text-align: justify ; vertical-align: middle; vertical-align: top ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 25.0px; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Replay PIN:</td> <td style="text-align: justify ; vertical-align: middle; vertical-align: top ; ">10053968</td> </tr> <tr> <td> </td> <td> </td> </tr> </table> <p align="justify"><strong>About Nano Labs Ltd</strong></p> <p align="justify">Nano Labs Ltd is a leading Web 3.0 infrastructure and product solution provider, and crypto treasury company. Nano Labs is committed to the development of high throughput computing ("HTC") chips and high performance computing ("HPC") chips. Nano Labs has built a comprehensive flow processing unit ("FPU") architecture which offers solution that integrates the features of both HTC and HPC. In addition, Nano Labs has actively positioned itself in the crypto assets space, adopting BNB as its primary reserve asset. It has reserved in mainstream crypto currency, BNB, and established an integrated platform covering multiple business verticals, including HTC solutions, HPC solutions and iPollo Claw*. For more information, please visit the Company's website at: <a href="https://www.globenewswire.com/Tracker?data=6_NFE9SV42-mS4YuUehB60LLrz78D_FIt5AWzXr_pSbl8WGc-KhcXWKuV58-nVP7heDyaWwCKBQJwvf-sr9V1A==" rel="nofollow" target="_blank" rel="nofollow">ir.nano.cn</a>.</p> <p align="justify">*According to an industry report prepared by Frost & Sullivan.</p> <p align="justify"><strong>Forward-Looking Statements</strong></p> <p align="justify">This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, the Company's plan to appeal the Staff's determination, which can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control, which may cause the Company's actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.</p> <p align="justify"><strong>For investor and media inquiries, please contact:</strong></p> <p align="justify"><strong>Nano Labs Ltd</strong><br />Email: <a href="https://www.globenewswire.com/Tracker?data=dY2MsplSL_SSW_viu7MYLHLCqq9vEX_A3tjSpKCsjiwMkxPhKzKc4gQCR1Nltp3G-qa91DPPxbn_YZR5fOp1MA==" rel="nofollow" target="_blank" rel="nofollow"> [email protected] </a></p> <p align="justify"><strong>Ascent Investor Relations LLC</strong><br />Tina Xiao<br />Phone: +1-646-932-7242<br />Email: <a href="https://www.globenewswire.com/Tracker?data=h8cssbKD8e6i9LapsB7Wvd8hs4wmn5bOXkBgHiuOXr6A-HF_y9y-By0e_oWIArzujOX-THtx8W6ZyaGgnP0UaSECDkqRFrZUPK_ieCi0OfDwSnmuFPvs6b-FFVcBmiSo" rel="nofollow" target="_blank" rel="nofollow"> [email protected] </a></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"> <tr> <td colspan="10" style="width:100%;;text-align: center ; vertical-align: middle; "><strong>Consolidated Balance Sheets<br />(Unaudited)<br /></strong></td> </tr> <tr> <td colspan="10" style="width:100%;"> </td> </tr> <tr> <td style="width:60.5368%;;text-align: center ; vertical-align: middle; vertical-align: bottom ; "> </td> <td colspan="2" style="width:11.0338%;;text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>As of<br />December<br />31,</strong></td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td colspan="5" style="width:24.5527%;;text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>As of December 31,</strong></td> <td style="width:1.88867%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="width:60.5368%;;text-align: center ; vertical-align: middle; vertical-align: bottom ; "> </td> <td colspan="2" style="width:11.0338%;;border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td colspan="5" style="width:24.5527%;;border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>2025</strong></td> <td style="width:1.88867%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="width:60.5368%;;text-align: center ; vertical-align: middle; vertical-align: bottom ; "> </td> <td colspan="2" style="width:11.0338%;;border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>RMB</strong></td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td colspan="2" style="width:11.5308%;;border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>RMB</strong></td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td colspan="2" style="width:11.0338%;;border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>US$</strong></td> <td style="width:1.88867%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="width:60.5368%;;text-align: justify ; vertical-align: middle; vertical-align: bottom ; "><strong>ASSETS</strong></td> <td colspan="2" style="width:11.0338%;;text-align: center ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td colspan="2" style="width:11.5308%;;vertical-align: bottom ; "> </td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td colspan="2" style="width:11.0338%;;vertical-align: bottom ; "> </td> <td style="width:1.88867%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="max-width:61%; width:60.5368%; min-width:61%;;text-align: justify ; vertical-align: middle; vertical-align: bottom ; "><strong>Current assets:</strong></td> <td style="max-width:1%; width:0.994036%; min-width:1%;;vertical-align: bottom ; "> </td> <td style="max-width:10%; width:10.0398%; min-width:10%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="max-width:2%; width:1.98807%; min-width:2%;;vertical-align: bottom ; "> </td> <td style="max-width:1%; width:0.994036%; min-width:1%;;vertical-align: bottom ; "> </td> <td style="max-width:10%; width:10.5368%; min-width:10%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="max-width:2%; width:1.98807%; min-width:2%;;vertical-align: bottom ; "> </td> <td style="max-width:1%; width:0.994036%; min-width:1%;;vertical-align: bottom ; "> </td> <td style="max-width:10%; width:10.0398%; min-width:10%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="max-width:2%; width:1.88867%; min-width:2%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="width:60.5368%;;vertical-align: middle; text-align: left; padding-left: 10.0px; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Cash and cash equivalents</td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">32,431,081</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.5368%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">8,502,357</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">1,209,646</td> <td style="width:1.88867%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="width:60.5368%;;vertical-align: middle; text-align: left; padding-left: 10.0px; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Restricted cash</td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">418,722</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.5368%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">1,347,795</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">191,753</td> <td style="width:1.88867%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="width:60.5368%;;vertical-align: middle; text-align: left; padding-left: 10.0px; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Accounts receivable, net</td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">572,803</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.5368%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">281,446</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">40,042</td> <td style="width:1.88867%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="width:60.5368%;;vertical-align: middle; text-align: left; padding-left: 10.0px; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Inventories, net</td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">29,866,418</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.5368%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">13,693,374</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">1,948,181</td> <td style="width:1.88867%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="width:60.5368%;;vertical-align: middle; text-align: left; padding-left: 10.0px; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Prepayments</td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">4,606,066</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.5368%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">7,567,871</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">1,076,695</td> <td style="width:1.88867%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="width:60.5368%;;vertical-align: middle; text-align: left; padding-left: 10.0px; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Short-term investments</td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">-</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.5368%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">26,214,992</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">3,729,654</td> <td style="width:1.88867%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="width:60.5368%;;vertical-align: middle; text-align: left; padding-left: 10.0px; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Receivable for cryptocurrencies collateral</td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">-</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.5368%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">20,387,316</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: ...</tr></table><p><a href=https://www.benzinga.com/pressreleases/26/03/g51535439/nano-labs-announces-second-half-of-2025-financial-results?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel alt=Nano Labs Announces Second Half of 2025 Financial Results>Full story available on Benzinga.com</a></p>

#STOCKS#ECONOMY
finance_yahoo83d ago

How to invest in silver: A beginner's guide

Here's what you need to know about why silver is an attractive option, how to invest in silver for beginners, and the factors that affect its price.

#STOCKS#COMMODITIES
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
benzinga83d ago

PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

PAVmed strengthened its capital structure and relaunched its medical device portfolio under new leadership Veris Health advanced strategic partnership with OSU and progressed implantable physiological monitor toward FDA submission Lucid Diagnostics expanded EsoGuard healthcare system access and clinical evidence base Conference call and webcast to be held today, March 30, at 8:30 AM EST NEW YORK , March 30, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD ) ("Lucid") and Veris Health Inc. ("Veris"), and reported financial results for the fourth quarter and year ended December 31, 2025. Conference Call and Webcast The webcast will take place on Monday, March 30, 2026, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com . Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "PAVmed Business Update" to join. Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com. Business Update Highlights "Over the past two years, we've undertaken a series of deliberate, systematic actions to fix PAVmed's legacy capital structure and strengthen its balance sheet," said Lishan Aklog, M.D. , PAVmed's Chairman and Chief Executive Officer. "This process is now complete and we believe PAVmed is exceptionally well positioned to execute on its founding mission — to operate as a high-growth diversified commercial life sciences company with multiple independently financed subsidiaries operating under a shared services model. Veris is now well underway in the commercial phase of its strategic engagement with OSU-The James while progressing its implantable physiological monitor toward FDA submission. Lucid continues to maintain a strong commercial foundation as it approaches transformative Medicare coverage for EsoGuard. We have also relaunched PAVmed's medical device portfolio under experienced leadership and completed the licensing of our endoscopic esophageal imaging technology from Duke University, adding another potential growth engine to our pipeline." Highlights from the fourth quarter and recent weeks : PAVmed strengthened its balance sheet through the completion of a $30 million Series D preferred stock offering and a $15 million senior secured note financing. A portion of the proceeds from these activities was used to eliminate all previously outstanding convertible securities, removing a significant legacy capital structure overhang and extending the Company's cash runway. In addition, the Company issued $30 million in Series D warrants, which are callable upon the publication of a draft CMS coverage policy for Lucid's EsoGuard Esophageal DNA Test. PAVmed relaunched its medical device portfolio and appointed industry veteran Joseph Virgilio as Chief Business Officer of Medical Devices to oversee development and commercialization of its current and future device portfolio, including the PortIO implantable intraosseous vascular access device and endoscopic esophageal imaging technology licensed from Duke University. Veris advanced its strategic engagement with The Ohio State University's James Cancer Hospital, with the commercial phase well underway and full integration with the hospital's electronic health record (EHR) system now complete. Veris is engaged with its development and manufacturing partner for its implantable physiological monitor, supporting a planned late 2026 FDA 510(k) submission. Lucid Diagnostics announced fourth quarter and full year 2025 financial results and key business developments, including: Recognized $1.5 million in EsoGuard ® Esophageal DNA Test revenue for 4Q25 and processed 3,664 EsoGuard tests. Awarded U.S. Department of Veterans Affairs (VA) contract for EsoGuard, expanding access across the nation's largest integrated healthcare system serving approximately nine million veterans. Announced positive data from the largest reported real-world experience of esophageal precancer detection, evaluating Lucid's EsoGuard and EsoCheck ® Esophageal Cell Collection Device in nearly 12,000 at-risk patients. Financial Results : For the three months ended December 31, 2025, Operating expenses were approximately $6.9 million which include stock-based compensation expenses of $0.3 million. GAAP net loss attributable to common stockholders was approximately $1.8 million, or $(2.05) per common share on a diluted basis. As shown below and for the purpose of illustrating the effect of stock-based compensation and other non-cash income and expenses on the Company's financial results, the Company's non-GAAP adjusted loss was approximately $0.9 million or $(1.05) per common share. PAVmed had cash and cash equivalents of $1.5 million as of December 31, 2025, compared to $1.2 million as of December 31, 2024. The audited financial results for the year ended December 31, 2025 were filed with the SEC on Form 10-K on March 27, 2026, and are available at www.pavmed.com or www.sec.gov . PAVmed Non-GAAP Measures To supplement our financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company's financial results. These non-GAAP financial measures include net loss before interest, taxes, depreciation, and amortization (EBITDA) and non-GAAP adjusted loss, which further adjusts EBITDA for stock-based compensation expense, loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, and loss on debt extinguishment. The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not recognized terms under U.S. GAAP. Non-GAAP financial measures are presented with the intent of providing greater transparency to the information used by us in our financial performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information to assist investors, shareholders, and other readers of our financial statements in making comparisons to our historical financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, a substitute for, considered superior to, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures. Non-GAAP financial measures are provided to enhance readers' overall understanding of our current financial results and to provide further information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of our core operating results and business outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss, and its presentation is intended to help the reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, the loss on debt extinguishment and the corresponding accounting for non-cash charges on financial performance. In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods. A reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for the three months and year ended December 31, 2025 and 2024 are as follows: Condensed Consolidated Statement of Operations (Unaudited) For the three months ended December 31, For the year ended December 31, 2025 2024 2025 2024 (in thousands except per-share amounts) Revenue $ 52 $ 10 $ 71 $ 2,995 Operating expenses 6,853 5 198 21,877 47,482 Other (Income) Expense (4,046) (6 330) Full story available on Benzinga.com

#STOCKS
AcreTrader Delivers over $135M in Investor Returns From Farmland Dispositions
cision83d ago

AcreTrader Delivers over $135M in Investor Returns From Farmland Dispositions

Latest Exits Demonstrate the Historical Strength of Farmland as an Asset Class FAYETTEVILLE, Ark., March 30, 2026 /PRNewswire/ -- Acretrader LLC ("AcreTrader"), a Proterra farmland investment platform, announced the successful disposition of 57 farmland assets across 13 states. Funded on...

#COMMODITIES
Rupee breaches 95/USD level; settles at 94.78 against US dollar
dailyexcelsior83d ago

Rupee breaches 95/USD level; settles at 94.78 against US dollar

MUMBAI, Mar 30: The rupee on Monday breached the 95/USD-mark in intra-day trade on Monday and settled at 94.78 (provisional) against the American currency after Iran war escalation jolted global markets, fuelling rupee volatility and risk-off sentiment. Forex traders said the USD/INR pair witnessed high volatility and swung 165 paise during intra-day trade as the West Asia crisis entered the 31st day keeping energy markets nervous. At the interbank foreign exchange, the rupee opened at 93.62 and then gained further ground [...] The post Rupee breaches 95/USD level; settles at 94.78 against US dollar appeared first on Daily Excelsior .

#FOREX